Hoberman Kenneth
SEC CIK 1573722 · EDGAR
BoughtSold
Most active insiders at NVCT, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Mosseri Marlio Charles | 10% | $1.87M | — |
| 2 | BENTSUR RON | COB, CEO, Dir, 10% | $278.6K | — |
| 3 | Sanchez Juan | Dir | $75.3K | — |
| 4 | Kaplan Matthew L. | Dir | $64.2K | — |
| 5 | Poradosu Enrique | Chief Science, Business Off | — | — |
| 6 | Carson Michael J. | VP, Fin | — | — |
| 7 | Shemesh Shay | Chief Dev, Ops. Off | — | — |
| 8 | Hoberman Kenneth | Dir | — | — |
| 9 | Oliviero James F III | Dir | — | — |
Transactions 9
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-12 16:12 | 2026-06-11 | NVCT | Nuvectis Pharma, Inc. | Hoberman Kenneth | Dir | A - Grant | $0.00 | +35.0K | 168.1K | +26% | $0 | |
| 2025-06-16 | 2025-06-12 | TGTX | TG THERAPEUTICS, INC. | Hoberman Kenneth | Dir | A - Grant | $0.00 | +14.7K | 279.7K | +6% | $0 | |
| 2025-06-12 | 2025-06-12 | NVCT | Nuvectis Pharma, Inc. | Hoberman Kenneth | Dir | A - Grant | $0.00 | +30.0K | 133.1K | +29% | $0 | |
| 2024-06-20 | 2024-06-19 | TGTX | TG THERAPEUTICS, INC. | Hoberman Kenneth | Dir | A - Grant | $0.00 | +22.2K | 264.9K | +9% | $0 | |
| 2024-06-13 | 2024-06-13 | NVCT | Nuvectis Pharma, Inc. | Hoberman Kenneth | Dir | A - Grant | $0.00 | +30.0K | 103.1K | +41% | $0 | |
| 2023-09-29 | 2023-09-28 | TGTX | TG THERAPEUTICS, INC. | Hoberman Kenneth | Dir | A - Grant | $0.00 | +20.0K | 242.7K | +9% | $0 | |
| 2023-06-20 | 2023-06-16 | NVCT | Nuvectis Pharma, Inc. | Hoberman Kenneth | Dir | A - Grant | $0.00 | +18.0K | 73.1K | +33% | $0 | |
| 2022-07-22 | 2022-07-20 | TGTX | TG THERAPEUTICS, INC. | Hoberman Kenneth | Dir | A - Grant | $0.00 | +43.7K | 222.7K | +24% | $0 | |
| 2022-05-16 | 2022-05-12 | NVCT | Nuvectis Pharma, Inc. | Hoberman Kenneth | Dir | P - Purchase | $17.40 | +6,000 | 55.1K | +12% | +$104.4K |
Purchase Sale Sale after option exercise All abbreviations